T
Tiffany Tang
Researcher at Cornell University
Publications - 103
Citations - 3624
Tiffany Tang is an academic researcher from Cornell University. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 25, co-authored 88 publications receiving 2480 citations. Previous affiliations of Tiffany Tang include NewYork–Presbyterian Hospital & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
TL;DR: The role of the CoV spike protein in mediating fusion of the viral and host cell membranes is reviewed, summarizing the results of research on SARS- CoV, MERS-CoV, and recent peer-reviewed studies of SARS -CoV-2, and it is suggested that the fusion mechanism be investigated as a potential antiviral target.
Journal ArticleDOI
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
Yok-Lam Kwong,Won Seog Kim,Soon Thye Lim,Seok Jin Kim,Tiffany Tang,Eric Tse,Anskar Y.H. Leung,Chor Sang Chim +7 more
TL;DR: Multivariate analysis showed that international prognostic index was the most significant factor impacting on outcome and survivals.
Journal ArticleDOI
Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
Ghee Chong Koo,Soo Yong Tan,Tiffany Tang,Song Ling Poon,George E. Allen,Leonard Tan,Soo Ching Chong,Whee Sze Ong,Kevin Tay,Miriam Tao,Richard Quek,Susan Loong,Kheng-Wei Yeoh,Swee Peng Yap,Kuo Ann Lee,Lay Cheng Lim,Daryl Tan,Christopher Goh,Ioana Cutcutache,Willie Yu,Cedric Chuan Young Ng,Vikneswari Rajasegaran,Hong Lee Heng,Anna Gan,Choon Kiat Ong,Steve Rozen,Patrick Tan,Bin Tean Teh,Soon Thye Lim +28 more
TL;DR: Functional characterization of the JAK3 mutations support its involvement in cytokine-independent JAK/STAT constitutive activation leading to increased cell growth, and targeting the deregulated Jak/STAT pathway could be a promising therapy for patients with NKTCLs.
Journal ArticleDOI
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Tammy Song,Maarja-Liisa Nairismagi,Yurike Laurensia,Jing Quan Lim,Jing Tan,Zhi Mei Li,Wan Lu Pang,Atish Kizhakeyil,Giovani Claresta Wijaya,Dachuan Huang,Sanjanaa Nagarajan,Burton Kuan Hui Chia,Daryl Ming Zhe Cheah,Yan Hui Liu,Fen Zhang,Hui Lan Rao,Tiffany Tang,Esther Kam Yin Wong,Jin Xin Bei,Jabed Iqbal,Jabed Iqbal,Nicholas Francis Grigoropoulos,Siok Bian Ng,Wee Joo Chng,Bin Tean Teh,Soo Yong Tan,Navin Kumar Verma,Hao Fan,Hao Fan,Soon Thye Lim,Choon Kiat Ong +30 more
TL;DR: It is demonstrated that STAT3 activation confers high PD-L1 expression, which may promote tumor immune evasion and the combination of PD-1/PD-L 1 antibodies and STAT3 inhibitors might be a promising therapeutic approach for NKTL, and possibly PTCL.
Journal ArticleDOI
Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group.
Eric Tse,Harinder Gill,Florence Loong,Seok Jin Kim,Siok Bian Ng,Tiffany Tang,Young-Hyeh Ko,Wee Joo Chng,Soon Thye Lim,Won Seog Kim,Yok-Lam Kwong +10 more
TL;DR: Age and the prognostic index for peripheral T‐cell lymphoma were not prognostically significant, and good performance status was associated with better OS and progression-free survival, and response to initial treatment led to betterOS and PFS.